Moleculin Biotech (NASDAQ:MBRX) Posts Quarterly Earnings Results, Misses Expectations By $0.72 EPS

Moleculin Biotech (NASDAQ:MBRX) released its quarterly earnings results on Friday. The company reported ($9.59) EPS for the quarter, missing analysts’ consensus estimates of ($8.87) by ($0.72), FiscalAI reports.

Moleculin Biotech Trading Down 2.4%

Shares of NASDAQ MBRX traded down $0.19 during trading hours on Friday, reaching $7.87. The stock had a trading volume of 9,899 shares, compared to its average volume of 46,415. Moleculin Biotech has a 52-week low of $3.23 and a 52-week high of $229.40. The firm has a market cap of $8.11 million, a price-to-earnings ratio of -0.06 and a beta of 2.11. The business’s fifty day moving average price is $9.94 and its two-hundred day moving average price is $36.71.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. Wall Street Zen downgraded shares of Moleculin Biotech from a “sell” rating to a “strong sell” rating in a research note on Saturday, November 7th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Moleculin Biotech in a research note on Thursday, October 15th. Finally, HC Wainwright reduced their price target on Moleculin Biotech to $60.00 and set a “buy” rating on the stock in a report on Friday, August 28th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $60.00.

Moleculin Biotech Company Profile

Moleculin Biotech is a clinical-stage pharmaceutical company based in Houston, Texas, focused on developing treatments for cancer and other serious diseases. Its research centers on drug candidates intended to address cancers that can be difficult to treat with existing therapies. The company’s pipeline includes Annamycin, an investigational anthracycline being studied for acute myeloid leukemia and soft-tissue sarcoma that has spread to the lungs. Moleculin has described Annamycin as designed to avoid some limitations associated with older anthracyclines, including heart-related toxicity.